Hospital
Lenox Hill Hospital
Lenox Hill Hospital was paid $63.17M by Medicaid between Jan 2018 and Dec 2024, across 335 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoLENOX HILL HOSPITAL
NEW YORK, NY 10075
NEW YORK, NY 10075
33aNPI1477616571assigned 12/19/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$63.17M
24GClaims869,370
24DCodes billed335
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New York
Rank by total paid#5 of 33
Median peer was paid$171K
This provider vs. median370×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,525 | $554K | |
| 2019 | 58,736 | $3.79M | |
| 2020 | 132,735 | $8.29M | |
| 2021 | 186,616 | $13.47M | |
| 2022 | 167,699 | $12.20M | |
| 2023 | 176,717 | $14.18M | |
| 2024incomplete | 134,342 | $10.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 37,645 | 33,744 | $6.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 33,088 | 30,877 | $5.51M |
| 19318 | 5.7% | 733 | 722 | $3.59M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 17,512 | 15,975 | $3.33M |
| 93458 | 4.1% | 1,179 | 1,161 | $2.58M | |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 3.3% | 11,586 | 3,632 | $2.10M |
| C1889 | Implantable/insertable device, not otherwise classified | 3.2% | 3,850 | 3,791 | $2.04M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 7,218 | 6,968 | $1.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 6,135 | 5,959 | $1.69M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 2.3% | 807 | 759 | $1.48M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 7,827 | 7,118 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 12,323 | 3,861 | $1.30M |
323 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.9% | 2,185 | $1.17M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.8% | 6,191 | $1.13M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.6% | 10,630 | $1.01M |
| 80053 | Comprehensive metabolic panel | 1.5% | 42,064 | $971K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 1,580 | $855K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 3,192 | $800K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 1,294 | $789K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.2% | 447 | $730K |
| 95800 | 1.0% | 1,020 | $640K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.0% | 379 | $637K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 102 | $606K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,125 | $571K |
| 58558 | <1% | 367 | $559K | |
| 42830 | <1% | 303 | $507K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,823 | $475K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 70 | $449K |
| 36415 | Collection of venous blood by venipuncture | <1% | 60,608 | $447K |
| C1769 | Guide wire | <1% | 2,771 | $434K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,045 | $412K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,610 | $412K |
| 30140 | <1% | 263 | $403K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 621 | $390K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,897 | $390K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,660 | $383K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,534 | $381K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 821 | $370K |
| 72197 | <1% | 723 | $368K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,572 | $365K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,402 | $332K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,960 | $325K |
| G0378 | Hospital observation service, per hour | <1% | 1,819 | $323K |
| 96415 | <1% | 892 | $322K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 673 | $289K |
| 75574 | <1% | 1,407 | $276K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,965 | $262K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,978 | $258K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,017 | $249K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 156 | $248K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,118 | $237K |
| 71250 | <1% | 1,607 | $227K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,075 | $222K |
| 93970 | <1% | 465 | $221K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,248 | $218K |
| 76641 | <1% | 2,021 | $210K | |
| 70486 | <1% | 1,855 | $206K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,580 | $202K |
| 70498 | <1% | 769 | $188K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,042 | $188K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 194 | $182K |
| 86900 | <1% | 4,194 | $175K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 768 | $175K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,188 | $173K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 371 | $172K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,594 | $164K |
| J3490 | Unclassified drugs | <1% | 15,570 | $162K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 109 | $157K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 332 | $156K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,933 | $141K |
| 86901 | <1% | 4,592 | $139K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 885 | $139K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,262 | $138K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,884 | $138K |
| 74183 | <1% | 278 | $128K | |
| 83880 | <1% | 4,464 | $126K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,244 | $126K |
| 97161 | <1% | 1,239 | $125K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,188 | $123K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,885 | $115K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 570 | $113K |
| 76536 | <1% | 1,423 | $111K | |
| 72141 | <1% | 249 | $107K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,145 | $103K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 161 | $102K |
| 93971 | <1% | 1,269 | $102K | |
| 86850 | <1% | 4,592 | $101K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,036 | $101K |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 83 | $99K |
| 30520 | <1% | 183 | $93K | |
| 70496 | <1% | 729 | $91K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 504 | $87K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,521 | $85K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,909 | $84K |
| 76801 | <1% | 1,022 | $83K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 237 | $77K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,320 | $77K |
| 88307 | <1% | 910 | $76K | |
| 73564 | <1% | 2,776 | $75K | |
| 76770 | <1% | 416 | $75K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 251 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 519 | $66K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,216 | $64K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,626 | $64K |
| 0225U | <1% | 2,522 | $63K | |
| 88321 | <1% | 408 | $62K | |
| 10060 | <1% | 159 | $60K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,057 | $60K |
| 82803 | <1% | 2,774 | $56K | |
| 88304 | <1% | 1,856 | $52K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,641 | $51K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,154 | $47K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,180 | $45K |
| 90715 | <1% | 1,585 | $43K | |
| 74174 | <1% | 145 | $43K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 187 | $42K |
| 87631 | <1% | 707 | $41K | |
| 76000 | <1% | 690 | $40K | |
| 86360 | <1% | 1,122 | $39K | |
| 73030 | <1% | 2,082 | $38K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,076 | $38K |
| 85610 | <1% | 13,132 | $38K | |
| 77336 | <1% | 315 | $37K | |
| 77065 | Tomosynthesis, mammo | <1% | 359 | $37K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 555 | $36K |
| 12001 | <1% | 73 | $35K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 630 | $34K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,367 | $32K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,197 | $32K |
| 70491 | <1% | 124 | $32K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,362 | $29K |
| 73610 | <1% | 1,930 | $29K | |
| 87536 | <1% | 1,409 | $28K | |
| 82962 | <1% | 15,223 | $28K | |
| 80061 | Lipid panel | <1% | 2,926 | $27K |
| 73630 | <1% | 2,026 | $27K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 53 | $27K |
| 96376 | <1% | 1,910 | $25K | |
| 73562 | <1% | 1,858 | $25K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,372 | $24K |
| 76870 | <1% | 284 | $24K | |
| 86359 | <1% | 1,344 | $24K | |
| 93454 | <1% | 13 | $24K | |
| 77066 | Tomosynthesis, mammo | <1% | 197 | $22K |
| 86703 | <1% | 1,590 | $22K | |
| 96367 | <1% | 234 | $22K | |
| 77085 | <1% | 87 | $21K | |
| 72131 | <1% | 147 | $21K | |
| 86480 | <1% | 313 | $21K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,362 | $21K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 447 | $20K |
| 88341 | <1% | 575 | $19K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 134 | $19K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 29 | $19K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 547 | $19K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,556 | $18K |
| C9399 | Unclassified drugs or biologicals | <1% | 474 | $18K |
| 73130 | <1% | 1,575 | $18K | |
| 73502 | <1% | 1,056 | $18K | |
| 72110 | <1% | 478 | $18K | |
| 72100 | <1% | 911 | $18K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,753 | $16K |
| 73110 | <1% | 946 | $16K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 97 | $15K |
| 77080 | <1% | 161 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,978 | $14K |
| V2632 | Posterior chamber intraocular lens | <1% | 143 | $14K |
| 70544 | <1% | 36 | $14K | |
| 81025 | <1% | 4,217 | $14K | |
| 84702 | <1% | 7,262 | $13K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 209 | $13K |
| 80076 | <1% | 880 | $13K | |
| 85730 | <1% | 11,965 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 210 | $12K |
| C1782 | Morcellator | <1% | 25 | $12K |
| C1781 | Mesh (implantable) | <1% | 25 | $12K |
| 74240 | <1% | 202 | $12K | |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | <1% | 86 | $12K |
| 97165 | <1% | 119 | $11K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 55 | $11K |
| 95811 | <1% | 13 | $11K | |
| 85027 | <1% | 6,215 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,767 | $10K |
| 86769 | <1% | 487 | $10K | |
| 84999 | <1% | 82 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 295 | $9K |
| 83690 | <1% | 10,828 | $9K | |
| 88173 | <1% | 185 | $9K | |
| 70543 | <1% | 12 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,551 | $9K |
| 36000 | <1% | 259 | $8K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,003 | $8K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 709 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,364 | $7K |
| 74178 | <1% | 24 | $7K | |
| 81001 | <1% | 11,972 | $7K | |
| 84484 | <1% | 11,437 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,104 | $7K |
| 96417 | <1% | 102 | $7K | |
| 76818 | <1% | 76 | $7K | |
| 72170 | <1% | 384 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,112 | $6K |
| 82565 | <1% | 1,322 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 665 | $6K |
| 83735 | <1% | 8,699 | $6K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,207 | $6K |
| 59025 | Fetal non-stress test | <1% | 89 | $6K |
| 88342 | <1% | 111 | $6K | |
| 72082 | <1% | 122 | $6K | |
| 78195 | <1% | 13 | $6K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,062 | $6K |
| 82542 | <1% | 237 | $6K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 82 | $6K |
| 88360 | <1% | 75 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,395 | $5K |
| 81003 | <1% | 7,544 | $5K | |
| 86140 | <1% | 2,674 | $5K | |
| 83605 | <1% | 4,832 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 313 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,535 | $5K |
| 73521 | <1% | 194 | $4K | |
| 72158 | <1% | 12 | $4K | |
| 99152 | <1% | 939 | $4K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 513 | $4K |
| 87486 | <1% | 223 | $4K | |
| 87581 | <1% | 223 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,490 | $4K |
| 87070 | <1% | 1,181 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,141 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,779 | $4K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 472 | $4K |
| A0425 | Ground mileage, per statute mile | <1% | 2,299 | $3K |
| 86780 | <1% | 1,970 | $3K | |
| 88112 | <1% | 52 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 402 | $3K |
| 73590 | <1% | 236 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 156 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,421 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,954 | $3K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 13 | $3K |
| 92978 | <1% | 12 | $3K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 13 | $3K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,012 | $2K |
| 73080 | <1% | 251 | $2K | |
| 76098 | <1% | 12 | $2K | |
| 87040 | <1% | 2,398 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 942 | $2K |
| 93975 | <1% | 19 | $2K | |
| 76377 | <1% | 13 | $2K | |
| 94760 | <1% | 101 | $2K | |
| 87529 | <1% | 46 | $2K | |
| 87186 | <1% | 1,561 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,077 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $2K |
| 71271 | <1% | 31 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,397 | $2K |
| 82550 | <1% | 4,335 | $1K | |
| 88300 | <1% | 395 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 169 | $1K |
| 82553 | <1% | 3,136 | $1K | |
| 76642 | <1% | 12 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,096 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 177 | $1K |
| 86481 | <1% | 32 | $1K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 923 | $1K |
| 85379 | <1% | 2,898 | $1K | |
| 74241 | <1% | 16 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 905 | $984.30 |
| 87081 | <1% | 996 | $956.30 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 331 | $932.57 |
| 93017 | <1% | 29 | $916.10 | |
| 87507 | <1% | 13 | $914.08 | |
| 72050 | <1% | 25 | $840.10 | |
| 96130 | <1% | 17 | $814.80 | |
| 87075 | <1% | 182 | $747.49 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,221 | $746.88 |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 22 | $712.06 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 249 | $697.09 |
| 82330 | <1% | 1,049 | $664.26 | |
| 72052 | <1% | 25 | $661.46 | |
| 86803 | <1% | 841 | $619.94 | |
| 84100 | <1% | 1,272 | $606.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 91 | $510.99 |
| 94060 | <1% | 13 | $499.76 | |
| 87340 | <1% | 138 | $488.53 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 143 | $479.13 |
| 73090 | <1% | 39 | $416.53 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 210 | $410.68 |
| 86592 | <1% | 670 | $403.48 | |
| 84132 | <1% | 1,145 | $360.63 | |
| 86593 | <1% | 615 | $350.57 | |
| 84295 | <1% | 1,016 | $318.40 | |
| 87077 | <1% | 216 | $312.09 | |
| 80230 | <1% | 52 | $311.57 | |
| 94729 | <1% | 13 | $296.58 | |
| 94726 | <1% | 13 | $285.63 | |
| G0008 | Administration of influenza virus vaccine | <1% | 29 | $268.40 |
| 90656 | <1% | 21 | $264.41 | |
| 96131 | <1% | 18 | $263.40 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 39 | $232.03 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 15 | $206.47 |
| 99051 | <1% | 13 | $204.75 | |
| 85652 | <1% | 395 | $179.88 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 139 | $169.75 |
| 82728 | <1% | 257 | $166.92 | |
| 73140 | <1% | 128 | $148.56 | |
| 74018 | <1% | 12 | $105.91 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 160 | $101.93 |
| 84145 | <1% | 109 | $100.72 | |
| 87184 | <1% | 68 | $96.38 | |
| 87400 | <1% | 13 | $86.79 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 123 | $77.14 |
| 87205 | <1% | 130 | $70.86 | |
| 83615 | <1% | 83 | $70.37 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 30 | $69.49 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 47 | $51.13 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 15 | $50.55 |
| 85347 | <1% | 80 | $42.52 | |
| 82248 | <1% | 53 | $40.23 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 13 | $39.67 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 29 | $36.67 |
| 84550 | <1% | 50 | $34.29 | |
| 85384 | <1% | 29 | $34.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 12 | $33.00 |
| 82570 | <1% | 37 | $30.33 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 12 | $26.75 |
| 82010 | <1% | 99 | $20.58 | |
| 86706 | <1% | 24 | $20.20 | |
| 88302 | <1% | 13 | $19.31 | |
| 82607 | <1% | 12 | $15.08 | |
| 84156 | <1% | 21 | $11.01 | |
| 73060 | <1% | 15 | $7.97 | |
| 99080 | 0% | 1,112 | $0.00 | |
| 88311 | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (SENIOR VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.